{"filing":{"accession_number":"0001193125-26-365132","cik":"0001657677","ticker":"PBLS","company_name":"Parabilis Medicines, Inc.","form":"8-K","filing_date":"2026-08-25","report_date":"2026-08-22","primary_document":"ck0001657677-20260822.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526365132/ck0001657677-20260822.htm"},"events":[{"id":29474,"run_id":26990,"accession_number":"0001193125-26-365132","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Craig L. Tendler, M.D., was appointed as a director of Parabilis Medicines on August 22, 2026, to fill a newly created vacancy on the Board. Dr. Tendler brings over 30 years of oncology drug development experience, including two decades in senior leadership roles at Johnson \u0026 Johnson overseeing clinical development and medical affairs.","company_name":"Parabilis Medicines, Inc.","ticker":"PBLS","filing_date":"2026-08-25","form":"8-K","submitted_at":null,"items":[{"id":31769,"accession_number":"0001193125-26-365132","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Craig L. Tendler, M.D., as a director of Parabilis Medicines on August 22, 2026, to fill a newly created vacancy on the Board. While the disclosure also includes compensatory arrangements (equity award and retainer), the principal disclosed action is the appointment itself. Dr. Tendler's extensive oncology drug development experience at Johnson \u0026 Johnson and his role as a scientific advisor make this a material governance event affecting the composition and expertise of the Board.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:12:22.392847+00:00","company_name":"","ticker":null,"filing_date":""},{"id":31770,"accession_number":"0001193125-26-365132","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Craig L. Tendler, M.D. to the Board of Directors of Parabilis Medicines. The press release emphasizes his extensive 30+ years of oncology drug development experience, including two decades at Johnson \u0026 Johnson in senior leadership roles overseeing clinical development and medical affairs. His appointment to the board of a clinical-stage biopharmaceutical company is material to investors as it signals governance strengthening and brings significant industry expertise to guide the company's pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:12:22.392847+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31769,"accession_number":"0001193125-26-365132","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Craig L. Tendler, M.D., as a director of Parabilis Medicines on August 22, 2026, to fill a newly created vacancy on the Board. While the disclosure also includes compensatory arrangements (equity award and retainer), the principal disclosed action is the appointment itself. Dr. Tendler's extensive oncology drug development experience at Johnson \u0026 Johnson and his role as a scientific advisor make this a material governance event affecting the composition and expertise of the Board.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:12:22.392847+00:00","company_name":"Parabilis Medicines, Inc.","ticker":"PBLS","filing_date":"2026-08-25"},{"id":31770,"accession_number":"0001193125-26-365132","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Craig L. Tendler, M.D. to the Board of Directors of Parabilis Medicines. The press release emphasizes his extensive 30+ years of oncology drug development experience, including two decades at Johnson \u0026 Johnson in senior leadership roles overseeing clinical development and medical affairs. His appointment to the board of a clinical-stage biopharmaceutical company is material to investors as it signals governance strengthening and brings significant industry expertise to guide the company's pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:12:22.392847+00:00","company_name":"Parabilis Medicines, Inc.","ticker":"PBLS","filing_date":"2026-08-25"}]}